Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2020 Earnings Conference Call March 31, 2021 4:30 PM ET Company Participants Claudia Styslinger - IR, Argo Partners Russell Ellison - President and CEO Tim Chole - VP, Marketing Marc Hoffman - CMO Russell Skibsted - EVP, CFO and Chief Business Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical Fourth Quarter and Full Year 2020 Results Call. At this time all particip ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

® ROCKWELL | --- | --- | --- | --- | --- | |---------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | ROCKWELL MEDICAL, INC. | | | | | | TRANSFORMING IRON DEFICIENCY AND ANEMIA MANAGEMENT March 2021 | | | | | FORWARD-LOOKING STATEMENTS 2 Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell Medical's intention to commercialize Triferic® Dia ...

Financial Data and Key Metrics Changes - The company ended the third quarter with cash, cash equivalents, and investments of more than $67 million, with cash used in operating activities for the nine months ended September 30 being approximately $21 million, comparable to the same period last year [58] - Net sales for the third quarter were $15.3 million, which is comparable to the same period last year, with Triferic net sales for the three months ended September 30, 2020, being approximately $284,000 [59] - The net loss for the third quarter improved to approximately $7.4 million from $7.9 million in the third quarter of last year, driven primarily by reductions in both commercial and G&A spending [61] Business Line Data and Key Metrics Changes - The number of contracted patients for Triferic increased to approximately 3,400, translating to an annualized treatment volume of approximately 500,000, a meaningful increase compared to the last quarter [35] - The overall growth in Triferic sales was lower than expected due to restrictions on in-person visits to dialysis clinics, but virtual engagement tactics helped maintain progress [36][70] Market Data and Key Metrics Changes - The company is focused on expanding its global commercial reach, with significant progress in international partnerships, including in China, India, and South Korea [53][54][56] - The home infusion therapy market is rapidly growing, with over 3.2 million patients served annually, and an estimated 60% incidence of iron deficiency anemia in this patient population [23] Company Strategy and Development Direction - The company aims to maximize U.S. sales of Triferic Dialysate and the soon-to-be-launched Triferic AVNU, while also expanding global commercial reach and developing new indications for its FPC platform [19][63] - The top priority for new indications is FPC for treating iron deficiency anemia in patients undergoing home infusion therapy, with plans to submit a clinical development plan to the FDA [22][66] Management Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing challenges posed by the COVID-19 pandemic, which has impacted the dialysis industry and restricted access to clinics [30][33] - The company expects to see a reacceleration of adoption of Triferic once the pandemic begins to resolve, and is making final preparations for the commercial launch of Triferic AVNU [64] Other Important Information - The company has a solid core business generating over $60 million annually, with one branded product in the market and a second one about to be launched [15] - The company has entered into partnerships for the commercialization of Triferic in key international markets, which are expected to generate significant growth over time [16][56] Q&A Session Summary Question: Can you talk about any gating factors that are still required or needed to get through before the launch of Triferic AVNU? - The delay was minor and related to scheduling of the production of packaging, with no further manufacturing issues anticipated [77] Question: Can you provide any color on the gross margin in the quarter? - The improvement in gross margin was primarily due to product mix, with ongoing efforts to make processes more efficient and cost-effective [79] Question: How long is Wanbang expected to take to reach full enrollment in the pivotal Triferic trial in China? - Full enrollment is anticipated in the first half of 2023, depending on the speed of enrollment [83] Question: What is the status of the regulatory review in India? - There is no firm answer on when the suspension of regulatory review will be lifted, as it is related to the incidence rate of COVID-19 cases [84] Question: What is the status of the evaluation programs for Triferic AVNU? - The first evaluation programs started in early October, and it is too early to report comprehensive results [86]

Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2020 Earnings Conference Call November 9, 2020 4:20 PM ET Company Participants Claudia Styslinger – Investor Relations Russell Ellison - President, Chief Executive Officer & Director Tim Chole – Vice President, Marketing Russell Skibsted - Executive Vice President, Chief Financial Officer & Chief Business Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Blair Cohen - H.C. Wainwright & Co. Disclaimer: *NEW* We are providing this transcript ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|------------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | Q3 2020 FINANCIAL RESULTS AND BUSINESS UPDATE | | | | | | | | CALL PARTICIPANTS | --- | --- | |---------------------------------------|-------------------------------------------------| | Russell Ellison, M.D., M.Sc. | President and Chief Executive Officer | | Russell Skibsted | Chief Financial Officer, Chief Busine ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Claudia Styslinger - Assistant Vice President at Argot Partners, LLC Russell Ellison - President and Chief Executive Officer Marc Hoffman - Chief Medical Officer Tim Chole - Vice President of Marketing Angus Smith - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald L.P. Blair Cohen - HC Wainwright Operator Good afternoon, ladies and gentlemen, and thank you ...

Financial Data and Key Metrics Changes - Net sales for Q4 2019 were $15.5 million, a decrease from $16.9 million in Q4 2018 [23] - Net sales of hemodialysis concentrates were $15.3 million in Q4 2019, down from $16.8 million in Q4 2018, primarily due to a decrease in international concentrate sales [23] - Net sales of Triferic were approximately $2.28 million in Q4 2019, significantly up from $68,000 in Q4 2018 [24] - Operating loss improved to $7.4 million in Q4 2019 from $9.4 million in Q4 2018, attributed to reduced G&A expenditures [27] - Net loss for Q4 2019 was $7.3 million or $0.11 per share, compared to a net loss of $9.4 million or $0.17 per share in Q4 2018 [30] Business Line Data and Key Metrics Changes - The company entered into 10 additional contracts during Q4 2019, representing a 77% increase in clinics under contract compared to Q3 2019 [11] - More than 80% of customers were on Triferic on an ongoing basis, indicating strong market traction [11] Market Data and Key Metrics Changes - The company reported a 67% increase in the number of annualized treatments under contract from Q3 to Q4 2019, equating to an increase of 100,000 annualized treatments [11] - The market opportunity for Triferic in hemodialysis is potentially in excess of $1 billion globally [18] Company Strategy and Development Direction - The company aims to transform anemia management in ESRD patients and expand into other therapeutic indications over the next 3 to 5 years [7] - The launch of Dialysate Triferic in the U.S. and the anticipated approval of IV Triferic are key components of the company's strategy [22] - The company is also exploring partnerships for Triferic's commercialization in international markets, including India and China [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming PDUFA date for IV Triferic and the potential for expanding Triferic adoption both domestically and internationally [12][14] - The company expects to see continued acceleration of adoption of Dialysate Triferic in 2020, supported by successful evaluation programs [10] Other Important Information - The company has expanded its medical advisory board with renowned nephrologists to enhance its medical capabilities [16] - The real-world data program has grown to include 8 clinics with over 700 patients, with plans to double the number of clinics in early 2020 [17] Q&A Session Summary Question: How many of the 160 clinics do you anticipate using Triferic by the end of this year? - Management indicated that while specific numbers were not provided, they expect to significantly accelerate the pace of adoption through MDOs [36] Question: Any recent requests from FDA regarding MDA for IV Triferic? - Management confirmed normal correspondence with the FDA ahead of the PDUFA date and expressed excitement about the upcoming decision [38] Question: Timeline updates for regulatory approvals in Chile? - Management expects to have approval in Chile later this year after delays due to civil unrest [39] Question: Status of the FDA untitled letter regarding the website? - Management stated that they have removed certain references from the website and are in dialogue with the FDA to resolve the matter [39]

Triferic Overview - Rockwell Medical is a commercial-stage company focused on transforming anemia management, initially targeting ESRD[7] - Triferic is designed to replace iron and maintain hemoglobin without increasing ferritin levels[7] - The global Triferic market potential is estimated to exceed $1 billion[7] Triferic Clinical and Commercial Progress - Dialysate Triferic was launched in the U S in May 2019[10] - An NDA for I V Triferic was submitted in May 2019, with a PDUFA date of March 28, 2020[10, 13] - Clinical data is being collected from seven sites with over 500 patients, with initial data expected in Q1 2020[12] - Clinics adopting Triferic have shown a 75% conversion rate since launch[18] Market and Financial Position - Rockwell Medical generates over $60 million in annual revenue from dialysis concentrates[7] - The U S market for anemia management therapies in CKD is over $4 1 billion annually[40] - The company is the 2 supplier of dialysis concentrates in the U S [7] International Expansion - Partnerships are in place for Triferic in China, India, Canada, Peru, and Chile[11] - The estimated peak market opportunity in China is over $400 million[52] - The estimated peak market opportunity in Europe and Japan is over $600 million[53]

Rockwell Medical, Inc. (NASDAQ:RMTI) Q3 2019 Results Conference Call November 11, 2019 4:30 PM ET Company Participants Judy DiClemente - In-Site Communications, Investor Relations Stuart Paul - President and Chief Executive Officer Angus Smith - Chief Financial Officer John McLaughlin - Chairman Conference Call Participants Brandon Folkes - Cantor Fitzgerald Chris Raymond - Piper Jaffray Edward Marks - H.C. Wainwright Operator Good day, ladies and gentlemen. And welcome to the Rockwell Medical 2019 Q3 Resul ...